FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

FAK活性维持卵巢癌对铂类化疗的固有耐药性和获得性耐药性

阅读:8
作者:Carlos J Diaz Osterman # ,Duygu Ozmadenci # ,Elizabeth G Kleinschmidt # ,Kristin N Taylor # ,Allison M Barrie # ,Shulin Jiang # ,Lisa M Bean # ,Florian J Sulzmaier # ,Christine Jean ,Isabelle Tancioni ,Kristen Anderson ,Sean Uryu ,Edward A Cordasco ,Jian Li ,Xiao Lei Chen ,Guo Fu ,Marjaana Ojalill ,Pekka Rappu ,Jyrki Heino ,Adam M Mark ,Guorong Xu ,Kathleen M Fisch ,Vihren N Kolev ,David T Weaver ,Jonathan A Pachter ,Balázs Győrffy ,Michael T McHale ,Denise C Connolly ,Alfredo Molinolo ,Dwayne G Stupack ,David D Schlaepfer

Abstract

Gene copy number alterations, tumor cell stemness, and the development of platinum chemotherapy resistance contribute to high-grade serous ovarian cancer (HGSOC) recurrence. Stem phenotypes involving Wnt-β-catenin, aldehyde dehydrogenase activities, intrinsic platinum resistance, and tumorsphere formation are here associated with spontaneous gains in Kras, Myc and FAK (KMF) genes in a new aggressive murine model of ovarian cancer. Adhesion-independent FAK signaling sustained KMF and human tumorsphere proliferation as well as resistance to cisplatin cytotoxicity. Platinum-resistant tumorspheres can acquire a dependence on FAK for growth. Accordingly, increased FAK tyrosine phosphorylation was observed within HGSOC patient tumors surviving neo-adjuvant chemotherapy. Combining a FAK inhibitor with platinum overcame chemoresistance and triggered cell apoptosis. FAK transcriptomic analyses across knockout and reconstituted cells identified 135 targets, elevated in HGSOC, that were regulated by FAK activity and β-catenin including Myc, pluripotency and DNA repair genes. These studies reveal an oncogenic FAK signaling role supporting chemoresistance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。